Evidence map›Paper›PMID 30147673›Full record

ReviewFrontiers in endocrinology2018

Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.

Takako Araki, Ning-Ai Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Cushing's Disease.Journal of clinical medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Takako ArakiDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
Ning-Ai LiuDepartment of Medicine, Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Cedars-Sinai Medical Center · USUniversity of Minnesota · US

Funding

Training Program in Endocrinology, Diabetes, and MetabolismT32DK007770 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 1999 to 2022
$3.4M
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovitR21DK103198 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 2014 to 2015
$445k
NIDDK NIH HHS R21 DK103198NIDDK NIH HHS T32 DK007770
6 · The paper itself

Abstract

Cell cycle proteins are critical to pituitary development, but their contribution to lineage-specific tumorigenesis has not been well-elucidated. Emerging evidence from

Indexed as

cell cycleCushing diseasecyclin EE2F1pituitary tumorPOMC

Identifiers

PMID30147673
PMCPMC6096271
OpenAlexW2885728701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.